These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11642742)

  • 1. Gene therapy for Parkinson's disease: recent achievements and remaining challenges.
    Castro MG; David A; Hurtado-Lorenzo A; Suwelack D; Millan E; Verakis T; Xiong WD; Yuan XP; Lowenstein PR
    Histol Histopathol; 2001 Oct; 16(4):1225-38. PubMed ID: 11642742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain-targeted delivery of neuroprotective survival gene minimizing hematopoietic cell contamination: implications for Parkinson's disease treatment.
    Lee MH; Kang S; Um KH; Lee SW; Hwang H; Baek K; Choi JW
    J Transl Med; 2024 Jan; 22(1):53. PubMed ID: 38218903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scientific rationale for the development of gene therapy strategies for Parkinson's disease.
    Björklund T; Kirik D
    Biochim Biophys Acta; 2009 Jul; 1792(7):703-13. PubMed ID: 19254760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanotechnology As Potential Tool for siRNA Delivery in Parkinson's Disease.
    Cortes H; Alcala-Alcala S; Avalos-Fuentes A; Mendoza-Munoz N; Quintanar-Guerrero D; Leyva-Gomez G; Floran B
    Curr Drug Targets; 2017 Nov; 18(16):1866-1879. PubMed ID: 28325145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
    Janelidze S; Nordström U; Kügler S; Brundin P
    J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultrasound targeted CNS gene delivery for Parkinson's disease treatment.
    Fan CH; Lin CY; Liu HL; Yeh CK
    J Control Release; 2017 Sep; 261():246-262. PubMed ID: 28690161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease.
    Bowers WJ; Howard DF; Federoff HJ
    Exp Neurol; 1997 Mar; 144(1):58-68. PubMed ID: 9126153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Therapy for Parkinson's Disease.
    Sudhakar V; Richardson RM
    Prog Neurol Surg; 2018; 33():253-264. PubMed ID: 29332089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo gene delivery for development of mammalian models for Parkinson's disease.
    Ulusoy A; Bjorklund T; Hermening S; Kirik D
    Exp Neurol; 2008 Jan; 209(1):89-100. PubMed ID: 18028909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy in Parkinson's disease.
    Eberhardt O; Schulz JB
    Cell Tissue Res; 2004 Oct; 318(1):243-60. PubMed ID: 15322915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral vector delivery of neurotrophic factors for Parkinson's disease therapy.
    Kelly MJ; O'Keeffe GW; Sullivan AM
    Expert Rev Mol Med; 2015 May; 17():e8. PubMed ID: 25997719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene-targeting approaches for movement disorders: recent advances.
    Kaplitt MG
    Curr Opin Neurol; 2019 Aug; 32(4):566-570. PubMed ID: 31232714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease.
    Gasmi M; Herzog CD; Brandon EP; Cunningham JJ; Ramirez GA; Ketchum ET; Bartus RT
    Mol Ther; 2007 Jan; 15(1):62-8. PubMed ID: 17164776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lentiviral mediated gene delivery as an effective therapeutic approach for Parkinson disease.
    Kakoty V; K C S; Dubey SK; Yang CH; Kesharwani P; Taliyan R
    Neurosci Lett; 2021 Apr; 750():135769. PubMed ID: 33636285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications.
    Wong LF; Goodhead L; Prat C; Mitrophanous KA; Kingsman SM; Mazarakis ND
    Hum Gene Ther; 2006 Jan; 17(1):1-9. PubMed ID: 16409120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral vectors as a tool to model and treat Parkinson's disease.
    Bensadoun JC; Aebischer P
    Wien Klin Wochenschr; 2006 Oct; 118(19-20):568-70. PubMed ID: 17136329
    [No Abstract]   [Full Text] [Related]  

  • 17. Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease.
    Sun M; Kong L; Wang X; Holmes C; Gao Q; Zhang GR; Pfeilschifter J; Goldstein DS; Geller AI
    Hum Gene Ther; 2004 Dec; 15(12):1177-96. PubMed ID: 15684695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease.
    Xue YQ; Ma BF; Zhao LR; Tatom JB; Li B; Jiang LX; Klein RL; Duan WM
    Gene Ther; 2010 Jan; 17(1):83-94. PubMed ID: 19727138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.
    Mandel RJ; Burger C; Snyder RO
    Exp Neurol; 2008 Jan; 209(1):58-71. PubMed ID: 17916354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrastriatal Delivery of Integration-Deficient Lentiviral Vectors in a Rat Model of Parkinson's Disease.
    Lu-Nguyen NB; Broadstock M; Yáñez-Muñoz RJ
    Methods Mol Biol; 2016; 1448():175-84. PubMed ID: 27317181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.